Influences of diabetes on the development and progression of cardiovascular disease

IDF Diabetes Atlas. 4th edition. Brussels: IDF, 2009;104.

Highlander P. , Shaw GP Current pharmacotherapeutic concepts for the treatment of cardiovascular disease in diabetics. Ther Adv Cardiovasc Dis 2010;4:43-54.

Noble M. , Drake-Holland A. Hyperglycaemia and the vascular glycocalyx: the key to microalbuminuria and cardiovascular disease in diabetes mellitus? Br J Diabetes Vasc Dis 2010;10:66-70.

Broekhuizen LN , Mooij HL , Kastelein JJ et al. Endothelial glycocalyx as potential diagnostic and therapeutic target in cardiovascular disease. Curr Opin Lipidol 2009;20:57-62.

Singh D. , Winocour P. , Farrington K. Endothelial cell dysfunction, medial arterial calcification and osteoprotegerin in diabetes. Br J Diabetes Vasc Dis 2010;10:71-77.

D’Amelio P. , Isaia G. , Isaia GC The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. J Endocrinol Invest 2009;32:6-9.

O’Donoghue M. , Braunwald E. Natriuretic peptides in heart failure: should therapy be guided by BNP levels? Nat Rev Cardiol 2010;7:13-20.

Toth PP An urgent matter-identifying your patients’ cardiovascular risk and improving their outcomes. Commentary. J Fam Pract 2009; 58:S41-3.

Noman A. , George J. , Struthers A. A new use for B-type natriuretic peptide: to detect myocardial ischaemia in non-heart failure patients. Br J Diabetes Vasc Dis 2010;10:78-82.

van Wijk DF , Stroes ES , Kastelein JJ Lipid measures and cardiovascular disease prediction. Dis Markers 2009;26:209-16.

Kuppuswamy V. , Mela M. , Eustace I. , Gupta S. Meeting UK national targets for lipids in acute coronary syndrome with early and intensive lipid reduction: a single centre district general hospital experience. Br J Diabetes Vasc Dis 2008;8:286-90.

National Collaborating Centre for Primary Care. NICE clinical guideline 67: Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: NICE, 2008.

Morrissey RP , Diamond GA , Kaul S. Statins in acute coronary syndromes: do the guideline recommendations match the evidence? J Am Coll Cardiol 2009;54:1425-33.

Devine M. , Chandrasekara W. , Hardy K. Management of hyperglycaemia in acute coronary syndrome. Br J Diabetes Vasc Dis 2010;10:.

Kuhlmann M. , Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis 2010;10:90-97.

Triay M. , Waheed M. Calciphylaxis. Br J Diabetes Vasc Dis 2010 ; 10:103-104.

Dweck M. , Francis M. Three vessel coronary ectasia in patient with previous cerebral malaria. Br J Diabetes Vasc Dis 2010;10:101-102.

United States Senate Committee on Finance: Staff report on GlaxoSmithKline and the diabetes drug Avandia. January 2010. http://finance.senate.gov/press/Gpress/2010/prg022010a.pdf (Accessed February 2010).

Nissen SE The rise and fall of rosiglitazone. Eur Heart J 2010 EPub ahead of print. http://eurheartj.oxfordjournals.org/content/early/2010/02/11/eurheartj.ehq016.extract (Accessed February 2010).

Krumholz H. A perspective on the American Heart Association Presidential Commission: advisory on thiazolidinedione drugs. Circ Cardiovasc Qual Outcomes 2010 EPub ahead of print. http://circ.ahajournals.org/cgi/content/abstract/CIR.0b013e3181d34114v1 (Accessed February 2010).

Schindler C. The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Ther Adv Cardiovasc Dis 2007 ;1:7-26.